Mesenchymal Stem Cells and Extracellular Vesicles: An Emerging Alternative to Combat COVID-19

Hugo . C. Rodriguez, Manu Gupta, Emilio Cavazos-Escobar, Enrique Montalvo, Saadiq F. El-Amin and Ashim Gupta

A chapter in Biotechnology to Combat COVID-19 from IntechOpen

Abstract: The global SARS-CoV-2 outbreak has been accompanied with severe socio-economic and health burdens that will ripple through history. It is now known that SARS-CoV-2 induces a cytokine storm that leads to acute respiratory distress syndrome and systemic organ damage. With no definitive nor safe therapy for COVID-19 as well as the rise of viral variants the need for an urgent treatment modality is paramount. Mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) have long been praised for their anti-viral, anti-inflammatory and tissue regenerative capabilities. MSCs and their EVs are now being studied for their possible use as a treatment modality for COVID-19. In this review we explore their capabilities and outline the evidence of their use in ALI, ARDS and COVID-19.

Keywords: COVID-19; Coronavirus; SARS-CoV-2; Mesenchymal stem cells; Extracellular vesicles; Exosomes; Regenerative medicine (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.intechopen.com/chapters/76119 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ito:pchaps:231584

DOI: 10.5772/intechopen.97212

Access Statistics for this chapter

More chapters in Chapters from IntechOpen
Bibliographic data for series maintained by Slobodan Momcilovic ().